Sangam: A Confluence of Knowledge Streams

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

Show simple item record

dc.contributor 5  Division of Transplant Surgery, University of Michigan Medical Center, Ann Arbor, MI, USA
dc.contributor 1  Division of Nephrology, Hospital do Rim e Hipertensao, Sao Paolo, Brazil
dc.contributor 2  Transplant Centre IKEM, Prague, Czech Republic
dc.contributor 3  Servicio de Nefrologia, Hospital Ramon y Cajal, Madrid, Spain
dc.contributor 4  Royal Prince Alfred Hospital, Sydney, Australia
dc.contributor 6  Organ Transplant Services, Piedmont Hospital, Atlanta, GA, USA
dc.contributor 7  Divisione Nefrologia e Dialisi, Az. Osp. Niguarda Ca’ Granda, Milano, Italy
dc.contributor 8  Princess Alexandra Hospital, Brisbane, Qld, Australia
dc.contributor 9  Hospital das ClÍnicas – UNICAMP, Campinas, SP, Brazil
dc.contributor 10  Service de Nephrologie, CHU, HÔpital Cavale Blanche, Brest, France
dc.contributor 11  Santa Casa de MisericÓridia de Porto Alegre, RS, Brazil
dc.contributor 12  Lifelink Transplant Institute, Tampa General Hospital, Tampa, FL, USA
dc.contributor 13  Hospital Geral de Fortaleza – Setor de Transplante Renal, Fortaleza, Ceara, Brazil
dc.contributor 14  Department of Medical and Surgical Sciences, Policlinico Hospital, Padua, Italy
dc.contributor 15  Department of Medicine and Nephrology, Maggiore Hospital, Parma, Italy
dc.contributor 16  Business Unit Transplantation, Novartis Pharma AG, Basel, Switzerland
dc.creator Tedesco-Silva, Helio
dc.creator Vitko, Stefan
dc.creator Pascual, Julio
dc.creator Eris, Josette
dc.creator Magee, John C.
dc.creator Whelchel, John
dc.creator Civati, Giovanni
dc.creator Campbell, Scott
dc.creator Alves-Filho, Gentil
dc.creator Bourbigot, Bernard
dc.creator Garcia, Valter Duro
dc.creator Leone, John
dc.creator Esmeraldo, Ronaldo
dc.creator Rigotti, Paolo
dc.creator Cambi, Vincenzo
dc.creator Haas, Tomas
dc.date 2010-06-01T21:35:40Z
dc.date 2010-06-01T21:35:40Z
dc.date 2007-01
dc.date.accessioned 2022-05-19T12:38:22Z
dc.date.available 2022-05-19T12:38:22Z
dc.identifier Tedesco-Silva, Helio; Vitko, Stefan; Pascual, Julio; Eris, Josette; Magee, John C.; Whelchel, John; Civati, Giovanni; Campbell, Scott; Alves-Filho, Gentil; Bourbigot, Bernard; Garcia, Valter Duro; Leone, John; Esmeraldo, Ronaldo; Rigotti, Paolo; Cambi, Vincenzo; Haas, Tomas (2007). "12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients." Transplant International 20(1): 27-36. <http://hdl.handle.net/2027.42/74645>
dc.identifier 0934-0874
dc.identifier 1432-2277
dc.identifier http://hdl.handle.net/2027.42/74645
dc.identifier http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17181650&dopt=citation
dc.identifier 17181650
dc.identifier 10.1111/j.1432-2277.2006.00414.x
dc.identifier Transplant International
dc.identifier Hariharan S, McBride MA, Cherikh WS, et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
dc.identifier Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002; 346: 580.
dc.identifier Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit 2002; 24: 53.
dc.identifier Sehgal S. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
dc.identifier Schuler W, Cottens S, HÄberlin B, et al. SDZ RAD, a new rapamycin derivative: pharmacologic properties in vitro and in vivo. Transplantation 1996; 64: 36.
dc.identifier Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogenic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine. J Heart Lung Transplant 1999; 18: 150.
dc.identifier Schuurman H-J, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997; 64: 32.
dc.identifier Serkova N, Hausen B, Berry GJ, et al. Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine. J Pharmacol Exp Ther 2000; 294: 323.
dc.identifier Hausen B, Boeke K, Berry GJ, et al. Coadministration of Neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability by staggered simultaneous treatment. Transplantation 1999; 67: 956.
dc.identifier Vitko S, Margreiter R, Weimar W, et al. the RAD 201 Study Group. International, double-blind, parallel-group study of the safety and efficacy of Certican TM (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral ® and steroids. Am J Transplant 2001; 1 ( Suppl. 1 ): 474.
dc.identifier Kaplan B, Tedesco-Silva H, Mendez R, et al. the RAD 251 Study Group. Abstract 1339. North/South American, double-blind, parallel group study of the safety and efficacy of Certican TM (RAD) versus mycophenolate mofetil (MMF) in combination with Neoral ® and corticosteroids. Am J Transplant 2001; 1 ( Suppl. 1 ): 475.
dc.identifier Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first 3 months post-transplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion (Neoral ® ). Transplantation 2003; 76: 903.
dc.identifier Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
dc.identifier Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 2001; 70: 247.
dc.identifier Nankivell B, Gruenewald SM, Allen RD, Chapman JR. Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683.
dc.identifier Cockcroft D, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
dc.identifier Davidson J, Wilkinson A, Dantal J et al. New onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003; 75: S3.
dc.identifier Stefoni S, Midtved K, Cole E, et al. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine A microemulsion: results of a 12-month, randomized, multicenter study. Transplantation 2005; 79: 577.
dc.identifier Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced exposure cyclosporine in de novo renal transplant recipients: a 3-year phase II, randomized, multicenter, open-label study. Transplantation 2004; 78: 1332.
dc.identifier Lawen J, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation. Transplantation 2003; 75: 37.
dc.identifier Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48.
dc.identifier.uri http://localhost:8080/xmlui/handle/CUHPOERS/111962
dc.description Peer Reviewed
dc.description http://deepblue.lib.umich.edu/bitstream/2027.42/74645/1/j.1432-2277.2006.00414.x.pdf
dc.format 516142 bytes
dc.format 3109 bytes
dc.format application/pdf
dc.format text/plain
dc.format application/pdf
dc.publisher Blackwell Publishing Ltd
dc.rights Journal compilation 2007 European Society for Organ Transplantation
dc.subject Cyclosporine
dc.subject Efficacy
dc.subject Everolimus
dc.subject Renal Transplant
dc.subject Safety
dc.subject Medicine (General)
dc.subject Health Sciences
dc.title 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients
dc.type Article


Files in this item

Files Size Format View
j.1432-2277.2006.00414.x.pdf 516.1Kb application/pdf View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse